Key Takeaways
- • Prolific Machines announced the initial closing of a $50M Series B2 financing, led by growth-stage fund Atoms & Bits and Nant Capital.
- • The round brings the biotechnology company's total funding to over $100 million, according to the company's announcement as reported by Massinvestor.
- • Nant Capital is the investment organization within a portfolio of private and public health and life sciences companies founded by Patrick Soon-Shiong, M.D.
- • Prolific Machines is developing integrated optogenetics-enabled solutions aimed at biologics development and manufacturing, citing higher yields, on-target quality, and process control.
Summary
Emeryville, California-based Prolific Machines has announced the initial closing of its $50 million Series B2 financing, according to a report from Massinvestor dated October 14, 2026. The round is led by Atoms & Bits, a growth-stage fund, and Nant Capital, the investment organization within a portfolio of private and public health and life sciences companies founded by Patrick Soon-Shiong, M.D.
The company describes itself as a biotechnology firm advancing biologics development and manufacturing through integrated optogenetics-enabled solutions. It states that these solutions deliver breakthrough yields, superior on-target quality, and precise process control. The financing brings Prolific Machines' total funding to over $100 million.
The primary source does not disclose the total size of the closing beyond the $50 million Series B2 figure, the valuation, or the use of proceeds, and the initial closing suggests additional tranches may follow.
The company describes itself as a biotechnology firm advancing biologics development and manufacturing through integrated optogenetics-enabled solutions. It states that these solutions deliver breakthrough yields, superior on-target quality, and precise process control. The financing brings Prolific Machines' total funding to over $100 million.
The primary source does not disclose the total size of the closing beyond the $50 million Series B2 figure, the valuation, or the use of proceeds, and the initial closing suggests additional tranches may follow.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.